SALA DE PRENSA DE RENOWN

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

El monitoreo médico de signos vitales de BioIntelliSense y el centro de comandos centralizado de Renown Health crean un sistema escalable para optimizar los recursos críticos de atención médica y la eficiencia del flujo de trabajo del personal de enfermería DENVER CO Y RENO, NV. 6 DICIEMBRE DE 2021: BioIntelliSense, una empresa de monitoreo continuo de la salud y de inteligencia clínica, ha entablado una colaboración estratégica con Renown Health, una red integrada de atención médica sin fines de lucro compuesta de hospitales e instalaciones de atención médica que atiende a más de un millón de personas en Nevada y el noreste de California, para brindar atención más conveniente, eficaz y personalizada a los pacientes mediante monitoreo remoto continuo para la atención de pacientes internados, como también para el control de la salud en el hogar. This innovative program integrates BioIntelliSense’s FDA-cleared BioSticker™ wearable device into Renown Health’s state-of-the-art clinical remote monitoring services to address today’s significant healthcare workforce shortage challenges and enhance their patient-centered model of care. BioIntelliSense’s BioSticker continuously monitors data on a patient’s skin temperature, resting heart rate and respiratory rate, step, gait, sleep, activity levels, and more, including infection-like symptom alerts that supports COVID-19 monitoring. The BioSticker’s medical-grade trending and advanced analytics will be visualized and monitored by clinical staff within the Renown Transfer and Operations Center (RTOC). The Renown Transfer and Operations Center is powered by Renown doctors, nurses, technicians and national technology partners, including BioIntelliSense, to help ensure seamless care for patients and providers. Through this highly coordinated care logistics system, Renown will be able to customize health care to the needs of every patient; delivering the right care, at the right time and place across the integrated delivery system. Renown clinicians will be able to access near real-time information on patients’ vital signs and symptoms, enabling them to identify adverse changes in health sooner and intervene earlier. “Given the growing healthcare workforce crisis, routine patient monitoring has become more expensive and less frequent, especially during the ongoing public health emergency.  With the BioSticker, vital signs monitoring can be provided for each patient far more frequently and at a fraction of the cost,” said James Mault, MD, Founder and CEO of BioIntelliSense. “Our strategic partnership with Renown Health serves as a gold standard demonstration project for other hospital systems. What we are learning from patients and providers at Renown will help create fully integrated, continuous care delivery that starts during the patient’s hospitalization enabling monitoring of their health status throughout their recovery process, and from the comfort of their own home after leaving the hospital.” During the first phase of the collaboration and during this phase one implementation, the BioSticker will be applied to all patients admitted to Renown’s community hospital, Renown South Meadows Medical Center in Reno, Nevada. Patients may wear the device throughout their hospital stay and continue to wear it when they leave for their homes, ambulatory, outpatient surgical, rehabilitation or skilled nursing settings. “We are excited to continue to enhance our relationships with patients by integrating technology that supplements our care teams and provides patients with a virtual care solution that will continuously track vital signs, making healthcare more accessible, affordable and convenient,” said Tony Slonim, MD, DPH, CEO, Renown Health. “We believe patients and their loved ones will have confidence in knowing that their Renown clinical team will be closely monitoring their health data and communicating with them regularly to deliver high quality, personalized care throughout their healing process.” Initially, this collaboration will focus on understanding the logistics of patient monitoring in the hospital and at home or remote sites using the BioIntelliSense remote care technology. Renown Health will then work towards streamlining and operationalizing the clinical workflow, while scaling the program, to measure clinical improvement and the economic impact on patient care. “We are entering a new era in continuous health monitoring, as innovative hospital systems like Renown Health are integrating remote care technologies that provide scalable, user friendly and cost-effective solutions for health screening, COVID symptom monitoring and remote patient monitoring,” noted Mault. “Prevemos que, en diez años, nuestros dispositivos portátiles se convertirán en el estándar de atención de las personas que no se sientan bien ya que les dará la tranquilidad a ellas mismas y a sus seres queridos de que están siendo monitoreados 24/7 por un equipo clínico comprensivo y tendrán la seguridad de que, si su afección empeora, podemos elevar el nivel de atención, de inmediato y en tiempo real”. "We are excited to serve as the national training site for BioIntelliSense and continue to bring new technology that improves the patient and provider experience to colleagues. We will continue to develop a well-trained, inter-professional and flexible workforce with technology skills that match the current pace of health care innovation,” added Slonim. “Our team is excited to be improving health care access and affordability across the state, and especially with critical access hospitals serving rural communities. Remote patient monitoring technology offers great benefit to patients at or near their homes, and it may transform hospital care by expanding access to clinical expertise to patients, and extending and increasing workforce capacity for limited hospital physician, nursing and clinical teams. We are pleased to be working with Dr. Mault and the team at BioIntelliSense, on the demonstration project with the BioSticker for vital signs monitoring as we take another bold step in innovating health care for long-term success.”     Acerca de Renown Health Renown Health es una red de atención médica integrada de administración local y sin fines de lucro que brinda servicios al norte de Nevada, Lake Tahoe y el noreste de California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, the region’s only children’s hospital, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to improving the care and the health of our community. Visite renown.org para obtener más información. About BioIntelliSense BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multiparameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ and medical grade BioButton® devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care from in the hospital to the home. Para obtener más información sobre cómo BioIntelliSense está redefiniendo el monitoreo remoto de pacientes con servicios de datos médicos económicos, escríbanos a info@biointellisense.com o visite nuestro sitio web en BioIntelliSense.com.

Leer más About Biointellisense and Renown Announce Strategic Collaboration

Dr. Max J. Coppes announced as Cancer Center Directory, Larry Duncan as Cancer Center Administrator for Renown's Institute for Cancer, with goal to improve the health and well-being of Nevadans. Renown Health is excited to announce that effective today, Max J. Coppes, MD, PhD, MBA has been appointed to a new leadership role as the Cancer Center Director for Renown’s Institute for Cancer. Dr. Coppes, a pediatric oncologist by training, has experience in leading large-scale, nationally-recognized academic adult and pediatric cancer center teams in both the U.S. and Canada. “If you know Dr. Coppes, you know he has the passion, dedication and commitment to build and foster the partnerships needed to create a leading comprehensive cancer center and program that spans the spectrum for patients and their families; from prevention to treatment to survivorship to palliative care,” said Tony Slonim, MD, DrPH, President and CEO, Renown Health. Also effective today, Larry Duncan, MS, has been appointed as Cancer Center Administrator for Renown Health, working in dyad partnership with Dr. Coppes to support the development of this important service line. Larry will also continue his service as Vice President of Pediatrics and Surgery & Administrator of Renown Children's & Women’s Services “Together, as they have done so successfully for Renown Children’s Hospital, Dr. Coppes and Larry Duncan will be responsible for the strategic direction, operations, fiscal management and recruitment of professionals to the Renown Institute for Cancer,” said Sy Johnson, MBA, chief of staff for Renown Health. “As one of Renown’s ‘Destination Health’ service lines, Dr. Coppes and Larry will continue to support an integrated leadership model that puts the patient at the center of all that we do.” El Dr. Coppes llegó a Reno en 2014 procedente de la British Columbia Cancer Agency de Vancouver, donde ocupó el cargo de presidente responsable de seis centros oncológicos regionales y dos centros de investigación del cáncer. He was an attending physician at BC Children's Hospital, an adjunct professor of Health Sciences at Simon Fraser University, and a professor of Medicine and Pediatrics at the University of British Columbia. During his career, Coppes served as senior vice president at Children's National Medical Center in Washington, D.C. and held positions at several prestigious facilities in the U.S. and Canada including The Hospital for Sick Children (SickKids) in Toronto, Georgetown University, The National Cancer Institute, and the Cleveland Clinic. Desde 2016, el Dr. Coppes se ha desempeñado en el rol de liderazgo conjunto como presidente de Pediatría del centro Nell J. Redfield de la Facultad de Medicina de la University of Nevada y pediatra en jefe del Renown Children’s Hospital, un puesto que ha sido posible gracias al generoso apoyo filantrópico de la Nell J. Redfield Foundation junto con las inversiones de Renown Health y la Facultad de Medicina de la UNR. Over the last five years, Duncan has served as Vice President of Pediatrics and Surgery & Administrator of Renown Children's and Women's Hospital, with oversight for Renown’s Pediatric Emergency Room and general and specialty pediatric physician practices. He has also served as Chief Operating Officer for Renown Regional Medical Center with oversight of pharmacy, imaging, nutrition, laboratory services and operating rooms. Antes de llegar a Renown, Duncan fue director general de El Paso Children’s Hospital y ocupó cargos ejecutivos en el Children’s Hospital of Wisconsin, el Children’s Hospital of Philadelphia y el Rush University Medical Center. “El Renown Institute for Cancer cuenta con la acreditación completa y distinción de la Comisión sobre el Cáncer del American College of Surgeons en todas las 7 áreas. Solo el 25 % de los programas oncológicos alcanzan esta distinción, que reconoce la calidad de la atención integral y multidisciplinar al paciente. Renown is the only accredited Community Hospital Comprehensive Cancer program in northern Nevada to be selected, and one of only three programs statewide,” says Max J. Coppes, MD, PhD, MBA. “That is certainly an excellent foundation on which to build on, and such a gift for our community.”  “Renown’s cancer nurses, patient navigators, social workers, palliative care specialists, geneticists, nutritionists, clinical trial researchers, physical rehab specialists and the entire team provides prevention and screening to help reduce the incidence of cancer and reduce the late stage presentation of cancers,” says Larry Duncan, MS. “Helping patients and families navigate their journey begins at the time of diagnosis, with the help of our nurse navigators, and extends throughout the patient’s treatment. Estamos avanzando en la supervivencia a largo plazo y nos complace ser reconocidos por la naturaleza integral de nuestros programas de investigación, atención, educación y divulgación comunitaria”. De acuerdo con el Instituto Nacional del Cáncer, la tasa de mortalidad ajustada por edad de 153.5 en 100,000 habitantes debido al cáncer en el condado de Washoe ha experimentado una mejora significativa en los últimos años, y ahora cumple el objetivo nacional de salud de Healthy People para 2020, que consiste en reducir la tasa global de mortalidad por cáncer por debajo de 161.4 en 100,000 habitantes. El objetivo nacional de salud de Healthy People 2030 es reducir la tasa global de mortalidad por cáncer a 122.7 muertes en 100,000 habitantes. El Instituto Nacional del Cáncer (National Cancer Institute, NCI) define el cáncer como un término utilizado para describir enfermedades en las que células anormales se dividen sin control y son capaces de invadir otros tejidos. Según el NCI, existen más de 100 tipos diferentes de cáncer, pero el cáncer de mama, colon, pulmón, páncreas, próstata y recto produce la mayor cantidad de muertes anuales. Risk factors of cancer include but are not limited to; age, alcohol use, tobacco use, a poor diet, certain hormones, and sun exposure. Although some of these risk factors cannot be avoided -- such as age -- limiting exposure to avoidable risk factors may lower risk of developing certain cancers. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Health, Neurosciences and Robotic Surgery. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project® . Para obtener más información, visite www.renown.

Leer más About Renown Health anuncia el equipo de liderazgo del programa contra el cáncer